Bulk Pharmaceutical API Sources for JARDIANCE

Bulk Pharmaceutical API Sources for JARDIANCE

Vendor	Vendor Homepage	Vendor Sku	API Url
AbaChemScene		CS-0940
MedChemexpress MCE		HY-15409
Synblock Inc		PB23119
Molport		MolPort-027-720-828
AKos Consulting & Solutions		AKOS024464680

Bulk Active Pharmaceutical Ingredient (API) Sources for Jardiance

Last updated: February 19, 2026

This report identifies key bulk active pharmaceutical ingredient (API) manufacturers and supply chain considerations for Empagliflozin, the API in Jardiance. The analysis focuses on publicly available patent information, regulatory filings, and industry reports to provide insights relevant to R&D and investment decisions.

What is Jardiance (Empagliflozin) and its Market Significance?

Jardiance, developed by Boehringer Ingelheim and Eli Lilly and Company, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used to treat type 2 diabetes mellitus. It functions by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. The drug has demonstrated efficacy in reducing cardiovascular events and heart failure hospitalizations in patients with type 2 diabetes, expanding its therapeutic utility and market penetration.

The global market for SGLT2 inhibitors is projected to grow, driven by increasing diabetes prevalence, expanding indications, and favorable clinical trial outcomes. Jardiance holds a significant share of this market. As of the latest available data, Jardiance has achieved substantial sales figures, reflecting its commercial success. For example, in 2023, net sales for Jardiance were reported to be approximately $6.4 billion [1]. This market size underscores the importance of a robust and reliable API supply chain.

Who are the Primary Manufacturers of Empagliflozin API?

The manufacturing of Empagliflozin API is primarily controlled by the originating innovators, Boehringer Ingelheim and Eli Lilly, through their internal manufacturing capabilities or contracted third-party manufacturers. However, as patents approach expiration, or in regions with different patent landscapes, generic API manufacturers may emerge.

Innovator Manufacturing and Key Patents

Boehringer Ingelheim and Eli Lilly hold the primary patents covering Empagliflozin and its manufacturing processes. These patents are critical for controlling the supply of the API during the exclusivity period.

• Key Composition of Matter Patent: U.S. Patent No. 7,829,530, titled "SGLT2 inhibitors," claims Empagliflozin. This patent is fundamental to the drug's exclusivity [2].
• Manufacturing Process Patents: Numerous patents detail specific synthesis routes for Empagliflozin. For example, U.S. Patent No. 8,575,347 B2, "Process for preparing empagliflozin," describes a particular synthetic pathway [3]. These process patents are crucial for understanding potential routes for generic competition.

The innovator companies may utilize their own manufacturing facilities or engage Contract Development and Manufacturing Organizations (CDMOs) for API production. Specific CDMO partnerships are often proprietary and not publicly disclosed. However, companies with demonstrated expertise in complex small molecule synthesis and cGMP (current Good Manufacturing Practice) compliance are potential candidates.

Potential Generic API Manufacturers

As patent exclusivity wanes, generic API manufacturers, particularly those based in India and China, are expected to play a more significant role. These regions are recognized for their large-scale API production capabilities and cost efficiencies.

Identifying specific generic API manufacturers at this stage is challenging, as many operate under confidentiality agreements or are in the process of developing their manufacturing routes and seeking regulatory approvals. However, based on industry trends and capabilities in API synthesis:

• Major Indian API Manufacturers: Companies such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Lupin, and Cipla are known for their extensive API portfolios and expertise in complex synthesis. They possess the infrastructure and regulatory compliance (e.g., US FDA, EMA) necessary for global API supply.
• Major Chinese API Manufacturers: Manufacturers like Zhejiang Huahai Pharmaceutical, Jiangsu Hengdian Group, and Fosun Pharmaceutical are significant players in the global API market. Their scale of production can offer cost advantages.

The entry of generic API manufacturers will be contingent on patent expiry dates in key markets and successful navigation of regulatory pathways, including the filing of Drug Master Files (DMFs) with regulatory agencies like the U.S. Food and Drug Administration (FDA).

What are the Key Manufacturing Process Considerations?

The synthesis of Empagliflozin involves multi-step chemical reactions. The efficiency, cost-effectiveness, and environmental impact of these processes are critical for API suppliers. Patents often describe specific intermediates, reagents, and reaction conditions.

A typical synthetic route for Empagliflozin involves several key steps. While detailed proprietary processes are not public, general approaches can be inferred from patent literature. These often involve:

1. Formation of the Glycoside Core: This step usually involves the reaction of a protected glucosyl donor with a substituted aromatic acceptor.
2. Functional Group Transformations: Subsequent steps involve deprotection of functional groups and further modifications to achieve the final Empagliflozin structure.
3. Chiral Synthesis or Resolution: Empagliflozin is a chiral molecule, and the correct stereoisomer must be produced. This can be achieved through asymmetric synthesis or chiral resolution techniques.

Key Chemical Transformations Often Employed:

• Glycosylation: Formation of the C-glycosidic bond.
• Protection/Deprotection Strategies: Use of protecting groups for hydroxyl functionalities on the sugar moiety.
• Suzuki Coupling or similar cross-coupling reactions: To introduce specific aryl substituents.
• Reduction reactions: To form specific stereocenters.

Critical Aspects for API Manufacturers:

• Yield and Purity: Maximizing reaction yields and achieving high purity levels (typically >99%) are paramount for pharmaceutical APIs.
• Cost of Goods: Efficient synthesis pathways, readily available raw materials, and minimized waste generation contribute to lower manufacturing costs.
• Scalability: Processes must be scalable from laboratory to commercial manufacturing volumes.
• Regulatory Compliance: Adherence to cGMP standards is mandatory for API production intended for regulated markets. This includes rigorous quality control, validation of processes, and impurity profiling.
• Impurity Control: Identification, characterization, and control of process-related impurities and degradation products are critical. This is often a focus of patent litigation and regulatory review.

What are the Patent Expirations and Market Entry Timelines?

The intellectual property landscape is a primary determinant of when generic API manufacturers can enter the market. Patent expiration dates for key patents on Empagliflozin are critical for investment and supply chain planning.

Key Patent Expiration Dates (U.S. Market Focus):

• U.S. Patent No. 7,829,530 (Composition of Matter): This patent, covering Empagliflozin itself, is a foundational patent. While the original term is typically 20 years from the filing date, patent term extensions (PTE) and adjustments can extend the effective market exclusivity. The filing date for this patent is February 21, 2007. Without extensions, it would expire around February 21, 2027. However, PTE can extend this. [2]
• Reissue Patent U.S. Patent No. RE45,777 E: This reissue patent claims similar subject matter. Its expiration is also crucial. [4]
• Process Patents: Numerous process patents for Empagliflozin have expiration dates that may offer earlier opportunities for generic entry if alternative, non-infringing synthesis routes can be developed. For example, U.S. Patent No. 8,575,347 B2, filed on October 28, 2011, with a publication date of November 5, 2013, would typically expire around November 5, 2033, assuming standard 20-year patent term from its filing date. [3]

Market Entry Considerations:

• Generic Drug Approval Process: Generic API manufacturers must obtain regulatory approval for their API, typically through a Drug Master File (DMF) submission to the FDA or equivalent dossiers in other regions. This process can take several years.
• Paragraph IV Certifications: Generic drug manufacturers seeking to enter the market before the expiration of listed patents often file Paragraph IV certifications under the Hatch-Waxman Act in the U.S. This initiates a 30-month stay period during which patent litigation may occur.
• Inter partes Review (IPR) and Post-Grant Review (PGR): These administrative proceedings before the U.S. Patent and Trademark Office (USPTO) can challenge the validity of patents, potentially leading to earlier market entry for generics.
• Geographic Variations: Patent laws and enforcement differ significantly by country, leading to varying market entry timelines for generic Empagliflozin API globally.

As of late 2023/early 2024, significant patent challenges and litigations are likely underway or will commence for Empagliflozin. This creates an uncertain but potentially lucrative environment for generic API manufacturers and pharmaceutical companies seeking to develop generic formulations.

What are the Regulatory and Quality Control Requirements for Empagliflozin API?

The production of Empagliflozin API for pharmaceutical use is subject to stringent regulatory oversight and quality control measures to ensure patient safety and drug efficacy.

Key Regulatory Bodies and Frameworks:

• U.S. Food and Drug Administration (FDA): Regulates drug manufacturing in the United States through cGMP guidelines. API manufacturers must comply with 21 CFR Part 210 and 211.
• European Medicines Agency (EMA): Oversees drug manufacturing within the European Union, adhering to EudraLex Volume 4, which details GMP requirements.
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): Provides guidelines that are widely adopted globally, including ICH Q7 for GMP for APIs.

Critical Quality Attributes (CQAs) for Empagliflozin API:

• Identity: Confirmation of the chemical structure of Empagliflozin.
• Assay: Quantitative determination of the API content (e.g., 98.0% to 102.0%).
• Purity: Strict limits on related substances, residual solvents, and elemental impurities.
  • Related Substances: Identification and quantification of process impurities and degradation products. Limits are set by pharmacopeial monographs or company specifications.
  • Residual Solvents: Compliance with ICH Q3C guidelines for solvents used in manufacturing.
  • Elemental Impurities: Compliance with ICH Q3D guidelines.
• Chiral Purity: Ensuring the correct enantiomer is present and controlling the levels of other stereoisomers.
• Particle Size Distribution: Can impact the dissolution rate and bioavailability of the finished drug product.
• Polymorphism: Control of crystalline form, as different polymorphs can have different physical properties and stability.

Quality Control Processes:

• In-process Controls (IPCs): Monitoring critical parameters during manufacturing steps.
• Release Testing: Comprehensive testing of the final API batch against pre-defined specifications before release.
• Stability Studies: Evaluating the API's stability under various storage conditions to determine shelf life and appropriate storage recommendations.
• Validation: Rigorous validation of manufacturing processes, analytical methods, and equipment.

Drug Master Files (DMFs):

API manufacturers typically submit a DMF to regulatory agencies (e.g., FDA, EMA). A DMF contains detailed confidential information about the manufacturing process, facilities, and quality controls for the API. It allows regulatory agencies to review the API information without disclosing proprietary details to the drug product manufacturer.

What are the Supply Chain Risks and Mitigation Strategies?

The global supply chain for pharmaceutical APIs, including Empagliflozin, faces various risks that can impact availability, cost, and quality.

Key Supply Chain Risks:

• Geopolitical Instability: Disruptions in major API manufacturing regions (e.g., China, India) due to political events, trade wars, or natural disasters.
• Regulatory Changes: New or revised GMP requirements, environmental regulations, or import/export restrictions can impact manufacturing and sourcing.
• Quality Failures and Recalls: Batch failures, contamination, or out-of-specification results can lead to product shortages and damage to supplier reputation.
• Intellectual Property Disputes: Patent litigation can lead to market entry delays or injunctions, affecting the supply of both innovator and generic APIs.
• Raw Material Shortages: Dependence on specific raw materials or intermediates can lead to price volatility and supply disruptions.
• Consolidation in Manufacturing: Mergers and acquisitions among API manufacturers can alter the competitive landscape and potentially reduce supplier options.
• Logistics and Transportation: Delays or disruptions in global shipping and logistics can impact timely delivery.

Mitigation Strategies:

• Dual Sourcing: Establishing relationships with multiple qualified API suppliers to reduce reliance on a single source. This requires rigorous supplier qualification and auditing.
• Geographic Diversification: Sourcing APIs from manufacturers located in different geographical regions to mitigate risks associated with localized disruptions.
• Robust Supplier Qualification and Auditing Program: Implementing thorough due diligence, site audits, and ongoing performance monitoring of API suppliers.
• Contingency Planning: Developing business continuity plans that address potential disruptions, including alternative manufacturing sites or inventory management strategies.
• Strategic Inventory Management: Maintaining adequate safety stock of critical raw materials and finished API, balanced against inventory carrying costs.
• Early Engagement with Regulatory Agencies: Proactively engaging with regulatory bodies to understand and comply with evolving requirements.
• Intellectual Property Due Diligence: Conducting comprehensive IP landscape analyses to understand patent risks and opportunities.
• Contractual Safeguards: Including clauses in supplier agreements that address supply continuity, quality assurance, and risk mitigation.

For Empagliflozin, the transition from innovator-controlled supply to a more diversified generic API market will require careful navigation of these risks by all stakeholders.

---

Key Takeaways

• Jardiance (Empagliflozin) is a significant product in the diabetes market, with substantial sales and growing indications, indicating a robust demand for its API.
• The primary API supply is currently controlled by innovators Boehringer Ingelheim and Eli Lilly.
• Key patents governing Empagliflozin, particularly the composition of matter patent (U.S. Patent No. 7,829,530), are critical to market exclusivity, with expirations guiding potential generic entry.
• Generic API manufacturers, predominantly from India and China, are expected to emerge as patent expiries approach, requiring significant investment in process development and regulatory compliance.
• Manufacturing processes for Empagliflozin involve complex multi-step synthesis, emphasizing the need for high yield, purity, scalability, and strict adherence to cGMP standards.
• The regulatory landscape, governed by agencies like the FDA and EMA, demands stringent quality control, impurity profiling, and detailed documentation (e.g., DMFs).
• Supply chain risks include geopolitical factors, regulatory changes, quality failures, and raw material shortages, necessitating strategies like dual sourcing, geographic diversification, and robust supplier management.

---

Frequently Asked Questions

1. When is the earliest U.S. market entry expected for generic Empagliflozin API, considering patent expiries? The earliest potential entry for generic Empagliflozin API in the U.S. market would likely be influenced by the expiration of the primary composition of matter patent (U.S. Patent No. 7,829,530) and any associated patent term extensions. Based on the filing date of February 21, 2007, the original patent term would expire around February 21, 2027. However, patent litigation, Paragraph IV certifications, and potential challenges via IPR/PGR proceedings can significantly alter this timeline.

2. What are the typical purity requirements for pharmaceutical-grade Empagliflozin API? Pharmaceutical-grade Empagliflozin API typically requires an assay purity of 98.0% to 102.0%. Strict limits are imposed on related substances (process impurities and degradation products), residual solvents, and elemental impurities, all of which are governed by ICH guidelines and pharmacopeial standards.

3. Are there any publicly disclosed CDMOs currently manufacturing Empagliflozin API for the innovators? Specific Contract Development and Manufacturing Organization (CDMO) partnerships for Empagliflozin API production by Boehringer Ingelheim or Eli Lilly are generally proprietary and not publicly disclosed. Innovator companies often utilize a combination of internal manufacturing and contracted services.

4. What are the main challenges for a new generic API manufacturer seeking to enter the Empagliflozin market? Key challenges include developing a non-infringing, cost-effective, and scalable manufacturing process; successfully navigating the complex regulatory approval process, including filing a robust DMF; overcoming potential patent litigation from the innovator companies; and establishing rigorous quality control systems to meet cGMP standards.

5. How do particle size distribution and polymorphism of Empagliflozin API affect the final drug product? Particle size distribution of the API can significantly influence the dissolution rate of the finished dosage form, impacting its bioavailability and therapeutic efficacy. Polymorphism, the existence of different crystalline forms, can affect the API's stability, solubility, and manufacturability, necessitating control over the crystalline form to ensure consistent drug product performance.

---

Citations

[1] Eli Lilly and Company. (2024). Eli Lilly and Company Reports Strong Fourth Quarter and Full-Year 2023 Financial Results. Retrieved from [Eli Lilly Investor Relations website] (Note: Specific URL would be added if available from a direct press release).

[2] U.S. Patent No. 7,829,530. (2010). SGLT2 inhibitors. Assignee: Boehringer Ingelheim International GmbH.

[3] U.S. Patent No. 8,575,347 B2. (2013). Process for preparing empagliflozin. Assignee: Boehringer Ingelheim International GmbH.

[4] U.S. Reissue Patent No. RE45,777 E. (2015). SGLT2 inhibitors. Assignee: Boehringer Ingelheim International GmbH.